Annexon, Inc. (NASDAQ:ANNX) Receives $15.80 Average Price Target from Brokerages

Shares of Annexon, Inc. (NASDAQ:ANNXGet Free Report) have received an average rating of “Buy” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $15.80.

ANNX has been the subject of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 target price on shares of Annexon in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Annexon in a research report on Tuesday, December 17th.

View Our Latest Analysis on ANNX

Institutional Investors Weigh In On Annexon

Several large investors have recently added to or reduced their stakes in the company. FMR LLC increased its holdings in Annexon by 3.2% in the 3rd quarter. FMR LLC now owns 8,561,949 shares of the company’s stock worth $50,687,000 after acquiring an additional 262,229 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in Annexon by 5.6% in the 4th quarter. Point72 Asset Management L.P. now owns 5,626,796 shares of the company’s stock worth $28,865,000 after acquiring an additional 299,798 shares during the last quarter. Vanguard Group Inc. increased its holdings in Annexon by 11.6% in the 4th quarter. Vanguard Group Inc. now owns 5,546,918 shares of the company’s stock worth $28,456,000 after acquiring an additional 576,625 shares during the last quarter. State Street Corp increased its holdings in Annexon by 116.6% in the 3rd quarter. State Street Corp now owns 3,841,879 shares of the company’s stock worth $22,744,000 after acquiring an additional 2,068,294 shares during the last quarter. Finally, Nuveen Asset Management LLC increased its holdings in Annexon by 6.5% in the 4th quarter. Nuveen Asset Management LLC now owns 2,720,485 shares of the company’s stock worth $13,956,000 after acquiring an additional 164,915 shares during the last quarter.

Annexon Trading Up 2.8 %

Shares of NASDAQ:ANNX opened at $2.60 on Thursday. The stock’s fifty day simple moving average is $3.49 and its two-hundred day simple moving average is $5.21. Annexon has a 1-year low of $2.30 and a 1-year high of $8.40. The stock has a market cap of $285.25 million, a PE ratio of -2.48 and a beta of 1.14.

Annexon (NASDAQ:ANNXGet Free Report) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.05). On average, sell-side analysts forecast that Annexon will post -0.96 earnings per share for the current fiscal year.

About Annexon

(Get Free Report

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.

See Also

Analyst Recommendations for Annexon (NASDAQ:ANNX)

Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.